Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide agonists, which work by stimulating/activating/enhancing the r… Read More

Showing promise in the landscape of obesity management, retatrutide represents a unique method. Beyond many existing medications, retatrutide works as a dual agonist, concurrently engaging both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) sensors. The simultaneous activation encourages multiple helpful effects, … Read More